Seeking Alpha

tvmanjon

tvmanjon
Send Message
View as an RSS Feed
View tvmanjon's Comments BY TICKER:
Latest  |  Highest rated
  • High-Risk Small Cap Biotech Keryx Pharma Has Become Overvalued [View article]
    Reporting insider sales selectively is biased. Bentsur and Oliviero have routinely sold shares since 2012 when shares were acquired through option exercises.
    Apr 1 09:21 AM | 3 Likes Like |Link to Comment
  • Keryx Biopharmaceuticals: Grim Realities Of The Dialysis Market Will Result In Commercial Failure [View article]
    Steve With the analysis you contend medical decisions are going to be made on an economic basis alone If I understand you correctly. It would be very helpful if a economic model defense was attached and not just asserting without numbers. This would be greatly appreciated in a post generic and post bundling scenario as you postulate. should I assume there is no medical benefit to Zerenex over the other options?
    Jan 22 11:19 AM | 3 Likes Like |Link to Comment
  • Celsion Prepares For Phase III Trial Redux [View article]
    The CEO is shady Stay away from Celsion
    Nov 27 08:10 AM | 1 Like Like |Link to Comment
  • Mastech Holdings: Holiday Gift for Investors [View article]
    Looks like you were spot on
    Oct 30 08:48 AM | Likes Like |Link to Comment
  • Navidea - Worth A Look? [View article]
    Very weak report. The DMC recommended halting the the Head and Neck trial because of exceptional results. It has been recently closed and Navidea is now in the process of preparing the SNDA.This report doesnt cover accurately how Lymphoseek works or the fact it is the first new treatment option in 30 years.Navidea is past the "speculitave stage".In the first few weeks on the market 2 major hospitals switched to Lymphoseek exclusively. This report way understates LS potential.
    Sep 4 08:59 AM | 2 Likes Like |Link to Comment
  • Navidea Biopharmaceuticals, Inc Management Discusses Q2 2013 Results - Earnings Call Transcript [View article]
    Your mistaken on 2q revenues. Quoted from the 2q transcript

    "For the 6 months ended June 30, 2013, Navidea's revenue was $195,000 compared to revenue of $72,000 for the same period in 2012.

    Revenue for the second quarter of 2013 included approximately $128,000 during the second quarter from the sale of Lymphoseek, including initial stocking of our partner's radiopharmacy."
    Aug 19 09:56 AM | Likes Like |Link to Comment
  • Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What? [View article]
    I agree.Listen to the conference call. Espically at the 25:53 mark. "Fundamentally going to change medicine" Thats a very strong statement.
    May 16 09:00 AM | Likes Like |Link to Comment
  • EDAP: The 'Holy Grail' In The Fight Against Prostate Cancer [View article]
    Only 32k procedures in all the host countries in 15 years. Hardly holy grail. It may be a great alternative but not a blockbuster.
    Feb 26 08:09 AM | Likes Like |Link to Comment
  • 5 Reasons Celsion Is Going To Go Even Higher [View article]
    "I sold none Tuesday". I'll explain. Did I miss it?
    Dec 12 05:29 AM | Likes Like |Link to Comment
COMMENTS STATS
9 Comments
9 Likes